Genetic Compensation of RUNX Family Transcription Factors in Leukemia

Overview

Journal Cancer Sci

Specialty Oncology

Date 2018 Jun 9

PMID 29883054

Citations 15

Authors

Yasuhiko Kamikubo

Affiliations

Soon will be listed here.

Abstract

Runt (Runt domain)-related transcription factor 1 (RUNX1) is a transcription factor belonging to the core-binding factor (CBF) family. It is considered to be a master regulator of hematopoiesis and has been regarded as a tumor suppressor because it is essential for definitive hematopoiesis in vertebrates. It is one of the most frequent target genes of chromosomal translocation in leukemia, and germ line mutation of RUNX1 causes familial platelet disorder with associated myeloid malignancies. Somatic cell mutations and chromosomal abnormalities, including those of RUNX1, are observed in myelodysplastic syndrome, acute myeloid leukemia, acute lymphoblastic leukemia, and chronic myelomonocytic leukemia at a high frequency. In addition, recent studies reported by us and other groups suggested that WT RUNX1 is needed for survival and proliferation of certain types of leukemia. In this review, we describe the significance and paradoxical requirement of RUNX1 tumor suppressor in hematological malignancies based on recent findings such as "Genetic compensation of RUNX family transcription factors in leukemia," "RUNX1 inhibition-induced inhibitory effects on leukemia cells through p53 activation" and our novel promising theory "Cluster regulation of RUNX (CROX)" through the RUNX gene switch method using pyrrole-imidazole polyamides as a new technique that could contribute to the next generation of leukemia treatment strategies.

Citing Articles

Novel biomarkers: the RUNX family as prognostic predictors in colorectal cancer.

Liu Y, Chen J, Li A, Wu Y, Ge J, Yuan M Front Immunol. 2025; 15:1430136.

PMID: 39822248 PMC: 11736411. DOI: 10.3389/fimmu.2024.1430136.

The unique functions of Runx1 in skeletal muscle maintenance and regeneration are facilitated by an ETS interaction domain.

Yu M, Thorner K, Parameswaran S, Wei W, Yu C, Lin X Development. 2024; 151(24).

PMID: 39508441 PMC: 11664167. DOI: 10.1242/dev.202556.

Exploring the role of the gene in hypoxia adaptation in Tibetan pigs.

Yan F, Wang Y, Wei M, Zhang J, Ye Y, Duan M Front Genet. 2024; 15:1339683.

PMID: 38680426 PMC: 11045884. DOI: 10.3389/fgene.2024.1339683.

RUNX1 C-terminal mutations impair blood cell differentiation by perturbing specific enhancer-promoter networks.

Jayne N, Liang Z, Lim D, Chen P, Diaz C, Arimoto K Blood Adv. 2024; 8(10):2410-2423.

PMID: 38513139 PMC: 11112616. DOI: 10.1182/bloodadvances.2023011484.

RUNX1-Survivin Axis Is a Novel Therapeutic Target for Malignant Rhabdoid Tumors.

Mikami M, Masuda T, Kanatani T, Noura M, Umeda K, Hiramatsu H Mol Cells. 2022; 45(12):886-895.

PMID: 36572559 PMC: 9794559. DOI: 10.14348/molcells.2022.2031.

References

Kamikubo Y, Hyde R, Zhao L, Alemu L, Rivas C, Garrett L . The C-terminus of CBFβ-SMMHC is required to induce embryonic hematopoietic defects and leukemogenesis. Blood. 2012; 121(4):638-42. PMC: 3557645. DOI: 10.1182/blood-2012-06-434688. View

Lukasik S, Zhang L, Corpora T, Tomanicek S, Li Y, Kundu M . Altered affinity of CBF beta-SMMHC for Runx1 explains its role in leukemogenesis. Nat Struct Biol. 2002; 9(9):674-9. DOI: 10.1038/nsb831. View

. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014; 511(7511):543-50. PMC: 4231481. DOI: 10.1038/nature13385. View

Sood R, Kamikubo Y, Liu P . Role of RUNX1 in hematological malignancies. Blood. 2017; 129(15):2070-2082. PMC: 5391618. DOI: 10.1182/blood-2016-10-687830. View

Kamikubo Y, Zhao L, Wunderlich M, Corpora T, Hyde R, Paul T . Accelerated leukemogenesis by truncated CBF beta-SMMHC defective in high-affinity binding with RUNX1. Cancer Cell. 2010; 17(5):455-68. PMC: 2874204. DOI: 10.1016/j.ccr.2010.03.022. View

Morita K, Maeda S, Suzuki K, Kiyose H, Taniguchi J, Liu P . Paradoxical enhancement of leukemogenesis in acute myeloid leukemia with moderately attenuated RUNX1 expressions. Blood Adv. 2018; 1(18):1440-1451. PMC: 5727854. DOI: 10.1182/bloodadvances.2017007591. View

Yan J, Liu Y, Lukasik S, Speck N, Bushweller J . CBFbeta allosterically regulates the Runx1 Runt domain via a dynamic conformational equilibrium. Nat Struct Mol Biol. 2004; 11(9):901-6. DOI: 10.1038/nsmb819. View

Warren A, Bravo J, Williams R, Rabbitts T . Structural basis for the heterodimeric interaction between the acute leukaemia-associated transcription factors AML1 and CBFbeta. EMBO J. 2000; 19(12):3004-15. PMC: 203359. DOI: 10.1093/emboj/19.12.3004. View

Ito Y, Bae S, Chuang L . The RUNX family: developmental regulators in cancer. Nat Rev Cancer. 2015; 15(2):81-95. DOI: 10.1038/nrc3877. View

10.

Renneville A, Roumier C, Biggio V, Nibourel O, Boissel N, Fenaux P . Cooperating gene mutations in acute myeloid leukemia: a review of the literature. Leukemia. 2008; 22(5):915-31. DOI: 10.1038/leu.2008.19. View

11.

Berardi M, Sun C, Zehr M, Abildgaard F, Peng J, Speck N . The Ig fold of the core binding factor alpha Runt domain is a member of a family of structurally and functionally related Ig-fold DNA-binding domains. Structure. 1999; 7(10):1247-56. DOI: 10.1016/s0969-2126(00)80058-1. View

12.

Ichikawa M, Asai T, Saito T, Seo S, Yamazaki I, Yamagata T . AML-1 is required for megakaryocytic maturation and lymphocytic differentiation, but not for maintenance of hematopoietic stem cells in adult hematopoiesis. Nat Med. 2004; 10(3):299-304. DOI: 10.1038/nm997. View

13.

Hyde R, Zhao L, Alemu L, Liu P . Runx1 is required for hematopoietic defects and leukemogenesis in Cbfb-MYH11 knock-in mice. Leukemia. 2015; 29(8):1771-8. PMC: 4526349. DOI: 10.1038/leu.2015.58. View

14.

Jain A, Allton K, Duncan A, Barton M . TRIM24 is a p53-induced E3-ubiquitin ligase that undergoes ATM-mediated phosphorylation and autodegradation during DNA damage. Mol Cell Biol. 2014; 34(14):2695-709. PMC: 4097665. DOI: 10.1128/MCB.01705-12. View

15.

Goyama S, Schibler J, Cunningham L, Zhang Y, Rao Y, Nishimoto N . Transcription factor RUNX1 promotes survival of acute myeloid leukemia cells. J Clin Invest. 2013; 123(9):3876-88. PMC: 3754260. DOI: 10.1172/JCI68557. View

16.

Liu P, Tarle S, Hajra A, Claxton D, Marlton P, Freedman M . Fusion between transcription factor CBF beta/PEBP2 beta and a myosin heavy chain in acute myeloid leukemia. Science. 1993; 261(5124):1041-4. DOI: 10.1126/science.8351518. View

17.

Miyoshi H, Shimizu K, Kozu T, Maseki N, Kaneko Y, Ohki M . t(8;21) breakpoints on chromosome 21 in acute myeloid leukemia are clustered within a limited region of a single gene, AML1. Proc Natl Acad Sci U S A. 1991; 88(23):10431-4. PMC: 52942. DOI: 10.1073/pnas.88.23.10431. View

18.

Allton K, Jain A, Herz H, Tsai W, Jung S, Qin J . Trim24 targets endogenous p53 for degradation. Proc Natl Acad Sci U S A. 2009; 106(28):11612-6. PMC: 2710642. DOI: 10.1073/pnas.0813177106. View

19.

Jain A, Barton M . Regulation of p53: TRIM24 enters the RING. Cell Cycle. 2009; 8(22):3668-74. DOI: 10.4161/cc.8.22.9979. View

20.

Kamikubo Y . Genetic compensation of RUNX family transcription factors in leukemia. Cancer Sci. 2018; 109(8):2358-2363. PMC: 6113440. DOI: 10.1111/cas.13664. View